These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

153 related items for PubMed ID: 1277211

  • 1. Deactivation of cyclophosphamide (NSC-26271) metabolites by sulfhydryl compounds.
    Draeger J, Peter G, Hohorst HJ.
    Cancer Treat Rep; 1976 Apr; 60(4):355-9. PubMed ID: 1277211
    [Abstract] [Full Text] [Related]

  • 2. The problem of oncostatic specificity of cyclophosphamide (NSC-26271): Studies on reactions that control the alkylating and cytotoxic activity.
    Hohorst HJ, Draeger U, Peter G, Voelcker G.
    Cancer Treat Rep; 1976 Apr; 60(4):309-15. PubMed ID: 1277206
    [Abstract] [Full Text] [Related]

  • 3. Cyclophosphamide (NSC-26271)-related phosphoramide mustards- recent advances and historical perspective.
    Friedman OM, Wodinsky I, Myles A.
    Cancer Treat Rep; 1976 Apr; 60(4):337-46. PubMed ID: 1277209
    [Abstract] [Full Text] [Related]

  • 4. Studies on the in vivo formation of acrolein: 3-hydroxy-propylmercapturic acid as an index of cyclophosphamide (NSC-26271) activation.
    Alarcon RA.
    Cancer Treat Rep; 1976 Apr; 60(4):327-35. PubMed ID: 1277208
    [Abstract] [Full Text] [Related]

  • 5. Studies on 4-hydroperoxycyclophosphamide (NSC-181815): a simple preparation method and its application for the synthesis of a new class of "activated" sulfur-containing cyclophosphamide (NSC-26271) derivatives.
    Peter G, Wagner T, Hohorst HJ.
    Cancer Treat Rep; 1976 Apr; 60(4):429-35. PubMed ID: 1277218
    [Abstract] [Full Text] [Related]

  • 6. Identification and pharmacokinetics of cyclophosphamide (NSC-26271) metabolites in vivo.
    Voelcker G, Wagner T, Hohorst HJ.
    Cancer Treat Rep; 1976 Apr; 60(4):415-22. PubMed ID: 1277216
    [Abstract] [Full Text] [Related]

  • 7. Comparative pharmacologic study in vitro and in vivo with cyclophosphamide (NSC-26271), cyclophosphamide metabolites, and plain nitrogen mustard compounds.
    Brock N.
    Cancer Treat Rep; 1976 Apr; 60(4):301-8. PubMed ID: 1277205
    [Abstract] [Full Text] [Related]

  • 8. Qualitative and quantitative investigations of cyclophosphamide (NSC-26271), cyclophosphamide metabolites, and related compounds by field-desorption mass spectrometry.
    Schulten HR.
    Cancer Treat Rep; 1976 Apr; 60(4):501-7. PubMed ID: 1277227
    [Abstract] [Full Text] [Related]

  • 9. Studies on the selective action of cyclophosphamide (NSC-26271): Inactivation of the hydroxylated metabolite by tissue-soluble enzymes.
    Cox PJ, Phillips BJ, Thomas P.
    Cancer Treat Rep; 1976 Apr; 60(4):321-6. PubMed ID: 179712
    [Abstract] [Full Text] [Related]

  • 10. Characterization of cyclophosphamide (NSC-26271) metabolites and related derivatives by field-desorption and electron-impact mass spectrometry.
    Przybylski M, Ringsdorf H, Voelcker G, Draeger U, Peter G, Hohorst HJ.
    Cancer Treat Rep; 1976 Apr; 60(4):509-16. PubMed ID: 1277228
    [Abstract] [Full Text] [Related]

  • 11. Two stable Fenton oxidation products of cyclophosphamide (NSC-26271) as precursors of 4-hydroxycyclophosphamide (NSC-196562) under physiologic conditions.
    Benckhuysen C, van der Steen J, Spanjersberg EJ.
    Cancer Treat Rep; 1976 Apr; 60(4):369-72. PubMed ID: 945125
    [Abstract] [Full Text] [Related]

  • 12. [Intracavitary chemotherapy of S 180 ascites sarcoma in mice with 4-(S-ethanol)-sulfido-cyclophosphamide in combination with protector thiols].
    Voelcker G, Jaschke A, Wrabetz E, Hohorst HJ.
    Arzneimittelforschung; 1984 Apr; 34(10):1291-8. PubMed ID: 6440565
    [Abstract] [Full Text] [Related]

  • 13. Thermodynamic analysis of the reaction of phosphoramide mustard with protector thiols.
    Seitz DE, Katterjohn CJ, Rinzel SM, Pearce HL.
    Cancer Res; 1989 Jul 01; 49(13):3525-8. PubMed ID: 2499418
    [Abstract] [Full Text] [Related]

  • 14. Conversion of 4-hydroperoxycyclophosphamide and 4-hydroxycyclophosphamide to phosphoramide mustard and acrolein mediated by bifunctional catalysis.
    Low JE, Borch RF, Sladek NE.
    Cancer Res; 1982 Mar 01; 42(3):830-7. PubMed ID: 7059981
    [Abstract] [Full Text] [Related]

  • 15. [Pharmacokinetics of cyclophosphamide and cyclophosphamide metabolites in the mouse and their influence on the therapeutic effect of "activated" cyclophosphamide (4-hydroxycyclophosphamide) (author's transl)].
    Voelcker G, Haeglsperger R.
    Arzneimittelforschung; 1982 Mar 01; 32(6):639-47. PubMed ID: 7202370
    [Abstract] [Full Text] [Related]

  • 16. The reaction of sulfhydryl groups with carbonyl compounds.
    Włodek L.
    Acta Biochim Pol; 1988 Mar 01; 35(4):307-17. PubMed ID: 3247807
    [Abstract] [Full Text] [Related]

  • 17. X-ray crystallographic studies of cyclophosphamide (NSC-26271) derivatives.
    Camerman A, Smith HW, Camerman N.
    Cancer Treat Rep; 1976 Apr 01; 60(4):517-22. PubMed ID: 1277229
    [Abstract] [Full Text] [Related]

  • 18. [S-Alkylmercapto groups for protection of the SH-function of cysteine. II. Thiol-disulfide exchange of asymmetric disulfides of cysteine].
    Weber U, Hartter P, Flohé L.
    Hoppe Seylers Z Physiol Chem; 1970 Nov 01; 351(11):1389-94. PubMed ID: 5479830
    [No Abstract] [Full Text] [Related]

  • 19. Aspects of the teratology of cyclophosphamide (NSC-26271).
    Ashby R, Davis L, Dewhurst BB, Espinal R, Penn RN, Upshall DG.
    Cancer Treat Rep; 1976 Apr 01; 60(4):477-82. PubMed ID: 1277224
    [Abstract] [Full Text] [Related]

  • 20. [Kinetics of the reaction of imidazole-SH-compounds with N-ethylmaleimide].
    Schneider F, Wenck H.
    Hoppe Seylers Z Physiol Chem; 1969 Dec 01; 350(12):1521-30. PubMed ID: 5363654
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.